Kawasaki Disease – Pipeline Review, H1 2012

Publication date: June 2012
Report size: 30 pages

Keywords : Kawasaki disease

Kawasaki Disease – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Kawasaki Disease - Pipeline Review, H1 2012', provides an overview of the Kawasaki Disease therapeutic pipeline. This report provides information on the therapeutic development for Kawasaki Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Kawasaki Disease – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Kawasaki Disease - Pipeline Review, H1 2012', provides an overview of the Kawasaki Disease therapeutic pipeline. This report provides information on the therapeutic development for Kawasaki Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kawasaki Disease. 'Kawasaki Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kawasaki Disease.
- A review of the Kawasaki Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kawasaki Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Kawasaki Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kawasaki Disease pipeline depth and focus of Kawasaki Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Pathology Industry in Australia

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Kawasaki Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Kawasaki Disease 7
Kawasaki Disease Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Kawasaki Disease Therapeutics – Products under Investigation by Universities/Institutes 13
Kawasaki Disease – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Remicade - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Cyclosporine - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Remicade + Immunoglobulin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Enbrel - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Immunoglobulin + Prednisolone - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Kawasaki Disease Therapeutics – Drug Profile Updates 25
Kawasaki Disease Therapeutics – Discontinued Products 26
Kawasaki Disease Therapeutics - Dormant Products 27
Kawasaki Disease – Product Development Milestones 28
Featured News & Press Releases 28
Aug 16, 2011: Octapharma Receives Australian Approval For Resupply Of Octagam 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables

Number of Products Under Development for Kawasaki Disease, H1 2012 7
Products under Development for Kawasaki Disease – Comparative Analysis, H1 2012 8
Number of Products under Investigation by Universities/Institutes, H1 2012 9
Comparative Analysis by Late Stage Development, H1 2012 10
Comparative Analysis by Mid Clinical Stage Development, H1 2012 11
Comparative Analysis by Early Clinical Stage Development, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 13
Assessment by Monotherapy Products, H1 2012 14
Assessment by Combination Products, H1 2012 15
Assessment by Stage and Route of Administration, H1 2012 17
Assessment by Stage and Molecule Type, H1 2012 19
Kawasaki Disease Therapeutics – Drug Profile Updates 25
Kawasaki Disease Therapeutics – Discontinued Products 26
Kawasaki Disease Therapeutics – Dormant Products 27

List of Figures

Number of Products under Development for Kawasaki Disease, H1 2012 7
Products under Development for Kawasaki Disease – Comparative Analysis, H1 2012 8
Products under Investigation by Universities/Institutes, H1 2012 9
Late Stage Products, H1 2012 10
Mid Clinical Stage Products, H1 2012 11
Early Clinical Stage Products, H1 2012 12
Assessment by Monotherapy Products, H1 2012 14
Assessment by Combination Products, H1 2012 15
Assessment by Route of Administration, H1 2012 16
Assessment by Stage and Route of Administration, H1 2012 17
Assessment by Molecule Type, H1 2012 18
Assessment by Stage and Molecule Type, H1 2012 19

Autoimmune Disease in Australia